Cleared Traditional

EZ-IO Intraosseous Vascular Access System (K180395) - FDA 510(k) Clearance

Class II General Hospital device cleared through predicate-based substantial equivalence.

K180395 · Arrow International, Inc. (Subsidiary of Teleflex, Inc.) · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2018
Decision
269d
Days
Class 2
Risk

K180395 is an FDA 510(k) clearance for the EZ-IO Intraosseous Vascular Access System. Classified as Needle, Hypodermic, Single Lumen (product code FMI), Class II - Special Controls.

Submitted by Arrow International, Inc. (Subsidiary of Teleflex, Inc.) (Reading, US). The FDA issued a Cleared decision on November 9, 2018 after a review of 269 days - an extended review cycle.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5570 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General Hospital review framework, consistent with the majority of Class II 510(k) submissions.

View all Arrow International, Inc. (Subsidiary of Teleflex, Inc.) devices

Submission Details

510(k) Number K180395 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 13, 2018
Decision Date November 09, 2018
Days to Decision 269 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
140d slower than avg
Panel avg: 129d · This submission: 269d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code FMI Needle, Hypodermic, Single Lumen
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5570
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. Clinical trial data may be submitted as supporting evidence to strengthen the substantial equivalence argument. Most General Hospital devices follow this clearance model.

Clinical Evidence

ClinicalTrials.gov
NCT01866475 Completed Interventional Industry-sponsored

Continuous Intraosseous Vascular Access Over 48 Hours

A Study to Determine the Safety of Continuous Intraosseous Vascular Access Over a Period of 48 Hours

127
Patients (actual)
1
Site
Other
Purpose
Open label
Masking
Condition studied Intraosseous Vascular Access
Study design Parallel
Eligibility All sexes · 21 Years+ · Healthy volunteers accepted
Principal investigator Emanuel DeNoia, MD
Sponsor Vidacare Corporation (industry)
Started 2014-11-01 → Primary completion 2016-07-01
Primary outcome
Serious Complications From Intraosseous (IO) Access
View full study on ClinicalTrials.gov

Regulatory Peers - FMI Needle, Hypodermic, Single Lumen

All 688
Devices cleared under the same product code (FMI) and FDA review panel - the closest regulatory comparables to K180395.
Verisafe Safety Sterile Needles (SSN)
K254273 · Promisemed Hangzhou Meditech Co., Ltd. · Apr 2026
Easydrip Classic Pen Needle
K252908 · Sandstone Medical (Suzhou), Inc. · Mar 2026
PRESSONE™
K253047 · Nipro Medical Corporation · Mar 2026
Safety Pen Needle
K253622 · Ningbo Medsun Medical Co., Ltd. · Mar 2026
Pen Needle
K252886 · Hh Global Technology, Inc. · Jan 2026
Pen Injector Needle 32.5
K250700 · Terumo Corporation · Nov 2025